Design Therapeutics (DSGN) Cash & Equivalents (2020 - 2026)

Design Therapeutics has reported Cash & Equivalents for 7 years, with the latest figure at $12.9 million in Q2 2026.

• Cash & Equivalents for Q2 2026 came in at $12.9 million, down 34.49% year-over-year; the trailing twelve-month figure through Jun 2026 was $12.9 million (down 34.49% YoY), and the FY2025 annual result was $16.9 million, down 25.29% from the prior year.
• Cash & Equivalents improved to $12.9 million in Q2 2026, from $12.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $287.3 million in Q1 2022 and troughed at $12.8 million in Q1 2026.
• A 5-year average of $44.5 million and a median of $26.8 million in 2022 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2022, when Cash & Equivalents plunged 91.12%; it then soared 68.03% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $26.5 million in 2022, then slipped by 20.0% to $21.2 million in 2023, then increased by 6.43% to $22.6 million in 2024, then slipped by 25.29% to $16.9 million in 2025, then decreased by 23.43% to $12.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $12.9 million in Q2 2026, $12.8 million in Q1 2026, and $16.9 million in Q4 2025.